TROXYCA ER Drug Patent Profile

Which patents cover Troxyca Er, and when can generic versions of Troxyca Er launch?

Troxyca Er is a drug marketed by Pfizer and is included in one NDA. There is one patent protecting this drug.

This drug has sixteen patent family members in twelve countries.

The generic ingredient in TROXYCA ER is naltrexone hydrochloride; oxycodone hydrochloride. There are nineteen drug master file entries for this compound. Additional details are available on the naltrexone hydrochloride; oxycodone hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Troxyca Er

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TROXYCA ER

International Patents:	16
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	2
DailyMed Link:	TROXYCA ER at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TROXYCA ER

Constraining patent/regulatory exclusivity:

7,815,934

NDA:

207621

Dosage:

CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TROXYCA ER

TROXYCA ER is protected by one US patents.

This potential generic entry date is based on patent 7,815,934.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TROXYCA ER	naltrexone hydrochloride; oxycodone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	207621-001	Aug 19, 2016		DISCN	No	No	7,815,934		Y
Pfizer	TROXYCA ER	naltrexone hydrochloride; oxycodone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	207621-004	Aug 19, 2016		DISCN	No	No	7,815,934		Y
Pfizer	TROXYCA ER	naltrexone hydrochloride; oxycodone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	207621-002	Aug 19, 2016		DISCN	No	No	7,815,934		Y
Pfizer	TROXYCA ER	naltrexone hydrochloride; oxycodone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	207621-003	Aug 19, 2016		DISCN	No	No	7,815,934		Y

Expired US Patents for TROXYCA ER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	TROXYCA ER	naltrexone hydrochloride; oxycodone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	207621-006	Aug 19, 2016	8,685,443
Pfizer	TROXYCA ER	naltrexone hydrochloride; oxycodone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	207621-001	Aug 19, 2016	8,685,443
Pfizer	TROXYCA ER	naltrexone hydrochloride; oxycodone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	207621-003	Aug 19, 2016	8,685,443
Pfizer	TROXYCA ER	naltrexone hydrochloride; oxycodone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	207621-005	Aug 19, 2016	8,685,443

International Patents for TROXYCA ER

See the table below for patents covering TROXYCA ER around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2003270778	SEQUESTERING SUBUNIT AND RELATED COMPOSITIONS AND METOHDS
Australia	2009251081	Sequestering subunit and related compositions and methods
Canada	2499550	SOUS-UNITE DE SEQUESTRATION ET COMPOSITIONS ET PROCEDES ASSOCIES (SEQUESTERING SUBUNIT AND RELATED COMPOSITIONS AND METHODS)
China	1703200	Sequestering subunit and related compositions and methods

Supplementary Protection Certificates for TROXYCA ER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2316456	LUC00054	Luxembourg		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330
2316456	2017C/064	Belgium		PRODUCT NAME: NALTREXONE/BUPROPION; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330
2316456	1790064-8	Sweden		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330
2316456	17C1058	France		PRODUCT NAME: NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION; REGISTRATION NO/DATE: EU/1/14/988 20150330

TROXYCA ER Market Dynamics and Financial Trajectory: Sales Trends, Pricing Pressure, Exclusivity Calendar, and Generic/Biosimilar Risk

Last updated: July 5, 2026

Executive summary: TROXYCA ER (tapentadol hydrochloride extended-release) is a niche, branded opioid with revenue driven by chronic pain prescribing, payer coverage and step edits, and competitive substitution toward lower-cost opioids and abuse-deterrent or alternative formulations. Financial trajectory is shaped by (1) opioid class scrutiny and utilization management, (2) brand-to-generic erosion where ANDA timing permits, and (3) the specific Orange Book and patent/exclusivity timetable for TROXYCA ER, which governs Paragraph IV leverage and settlement value. Absent the specific FDA/Orange Book listing, patent numbers, and the latest audited sales/trajectory data for TROXYCA ER, a complete, investment-grade forecast cannot be produced.

H1: TROXYCA ER (Tapentadol ER) Market Dynamics and Financial Trajectory

---

What is TROXYCA ER and where does it sell in the chronic pain market?

TROXYCA ER is an extended-release tapentadol formulation indicated for chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment that cannot be managed with alternative therapies. Commercial dynamics follow typical long-acting opioid patterns:

Key demand drivers

• Patient segmentation: Chronic non-cancer pain patients using long-acting opioids, including those switching from other ER opioids due to tolerability or payer edits.
• Provider behavior: Primary care and pain specialists that manage stable opioid regimens and avoid frequent regimen changes due to safety and regulatory scrutiny.
• Formulary placement: Preferred vs non-preferred status in commercial formularies and impacts from opioid quantity limits and step edits.
• Payer controls: Prior authorization (PA), claims edits, and dose caps.

Key inhibitors

• Opioid risk management rules: Increased monitoring, prescribing controls, and scrutiny of opioid volumes.
• Shift to alternatives: Uptake of non-opioid and non-ER opioid strategies when payer coverage tightens.
• Generic substitution: When ANDA entry is permitted and priced lower, channel inventory and prescriber switching can accelerate.

---

What is the Orange Book status of TROXYCA ER and which exclusivities govern entry?

Answer (featured snippet): TROXYCA ER’s FDA exclusivity and patent status determine whether ANDA filers can launch immediately or must wait for listed patent expiration and any remaining exclusivity periods.

What matters to market entry

• Listed patents in the Orange Book for the ER dosage form and strength(s).
• Patent expiration dates by claim scope: active ingredient, formulation, method of use, and manufacturing.
• Any 5-year new chemical entity exclusivity (unlikely for tapentadol ER given the class history) and 6-month/other exclusivities (pediatric, etc.) that can shift “fast-follow” ANDA launch timing.
• 30-month stay risk after Paragraph IV filings, which can delay first generic revenue.

Business relevance

• Patent and exclusivity structure determines:
  • Likelihood of Paragraph IV challenges
  • Probability of forfeiture risk for ANDA entrants
  • Expected settlement leverage and the time window for the brand to defend formulary position.

---

Which patents protect TROXYCA ER and how broad are they (formulation, method-of-use, and process)?

Answer (featured snippet): The strength and breadth of TROXYCA ER’s Orange Book patent estate determine generic entry risk, not just the number of patents.

Patent estate categories that drive freedom-to-operate

1. Drug substance/active ingredient patents
   • Broadest typically, highest friction for ANDA workarounds.
2. Formulation patents
   • ER matrix, coating, release mechanisms, or abuse-deterrent concepts (if present).
3. Method-of-use patents
   • Can delay approval for specific patient populations or dosing regimens if claim scope is narrow and Orange Book-listed for that NDA.
4. Manufacturing/process patents
   • Often less litigated than product/formulation but can raise knock-on barriers.

How to evaluate strength for TROXYCA ER (decision framework)

• Claim survivability: Whether patents are likely to withstand obviousness and anticipation attacks.
• Expiration clustering: If multiple patents expire late and cluster, generic entry can be delayed despite earlier expiring patents.
• Litigation history: Prior injunction or narrowing decisions signal risk of invalidation.
• Settlement precedent: If similar opioid ER products settled frequently, TROXYCA ER’s settlement leverage can be inferred.

---

When does TROXYCA ER lose exclusivity and what generic launch scenarios could occur?

Answer (featured snippet): The earliest date a generic can launch is the latest among (a) expiring listed Orange Book patents for the ANDA claim landscape and (b) any applicable non-patent exclusivities, plus any stay time triggered by Paragraph IV litigation.

Generic launch scenarios that impact revenue trajectory

• Scenario A: Design-around allowed
  • ANDA approval proceeds but launch is delayed until remaining protected claims expire.
• Scenario B: Paragraph IV + 30-month stay
  • Approval letter issued but launch stayed until litigation resolves or settlement occurs.
• Scenario C: Settlement with delayed launch
  • Brand pays or undertakes restrictions; generic launches on defined date, often after a risk-adjusted delay.
• Scenario D: Launch without settlement
  • If litigation weakens brand protection, launch can occur earlier than expected, accelerating price erosion.

Market impact on sales

• Initial generic penetration often causes:
  • Major discounting in covered channels
  • Conversion of new prescriptions to cheaper alternatives
  • Inventory dynamics that can cause step-down revenue spikes in quarters around first launch.

---

How strong is Paragraph IV litigation risk for TROXYCA ER?

Answer (featured snippet): Paragraph IV litigation risk is highest when brand patent coverage is older (weaker inventorship/obviousness resilience) and claim scope is narrow enough for ANDA entrants to design around.

What determines Paragraph IV activity

• Number and quality of Orange Book patents
• History of challenges for similar ER opioids
• Ease of proving bioequivalence
• Injunction risk and settlement norms

Why it matters financially

• A strong litigation and settlement profile extends branded revenue and improves forecasting accuracy for channel pricing and rebate strategy.
• A weak profile increases probability of rapid generic revenue attrition and sustained margin compression.

---

How does TROXYCA ER compare with competing tapentadol and other long-acting opioids?

Answer (featured snippet): Market share for TROXYCA ER is driven more by formulary access and payer policy than by pharmacology alone because ER opioids compete on net price after rebates, step edits, and coverage tiers.

Competitive set (commercially relevant peers)

• Other long-acting opioids: ER oxycodone products, ER morphine, ER hydromorphone, and ER oxymorphone derivatives.
• Other tapentadol formulations: If alternative tapentadol products (IR or other ER) have better payer access or lower cost.

Competitive positioning variables

• Coverage tier: Preferred brand vs non-preferred triggers utilization shifts.
• Net pricing: Rebate and discount structures tied to formulary performance.
• Abuse-deterrent and risk management: Payer preferences for ER products with abuse-deterrent labeling or lower diversion risk profiles.
• Switchability: Whether payers require step therapy from other opioids and whether patients can safely switch.

---

What is the FDA regulatory path for TROXYCA ER generics (ANDA vs 505(b)(2)) and what does it imply for timing?

Answer (featured snippet): Generic TROXYCA ER is typically an ANDA pathway; timing is driven by Orange Book-listed patents, exclusivities, and any litigation stays.

Timing mechanisms

• ANDA submission does not grant launch rights
• Paragraph IV triggers 30-month stay if applicable
• Bioequivalence standards control approval but not launch timing if patents remain in force

Implications

• Faster ANDA approval does not automatically translate into earlier branded sales erosion if patents remain enforceable.
• Launch timing is usually a function of the intersection between patent expiration and litigation/settlement calendars.

---

What market dynamics affect TROXYCA ER pricing, rebates, and net revenue?

Answer (featured snippet): Net revenue trajectory tracks formulary access and payer rebate pressure, then accelerates downward after generic launch due to wholesale price compression and increased utilization management.

Pricing pressure channels

• Rebate intensity: Payers with opioid policies tend to increase rebate leverage for preferred status.
• Working capital and inventory: Post-launch generic entry can force the brand to adjust distribution and marketing terms.
• Channel mix: Shifts between commercial, Medicaid managed care, and institutional/pain clinic channels affect net price volatility.

Utilization management dynamics

• Step therapy requirements and dose optimization can reduce patient starts and maintain or worsen adherence rates among existing users.

---

How do opioid class dynamics and enforcement risk influence TROXYCA ER financial outcomes?

Answer (featured snippet): Broad opioid risk policy reduces long-acting opioid growth and increases the probability of abrupt demand shifts during policy rollouts, payer edits, and regulatory enforcement.

Effects on revenue quality

• Lower net growth: Fewer new starts and more constrained refills in covered plans.
• Higher churn risk: Patients move to alternative therapies if access barriers tighten.
• Greater contracting pressure: Payers demand outcome-linked pricing or higher rebates.

---

Which companies are positioned to capture TROXYCA ER share during generic entry and what are the risks to the brand?

Answer (featured snippet): Generic entrants gaining ANDA approval and launch slots can capture share quickly through aggressive pricing, but the magnitude depends on whether the brand settles and on the number of strengths/packaging affected by launch.

Brand risk factors

• Single-strength launch vs broad launch: Partial strength erosion can be slower; broad strength entry tends to be faster and more damaging.
• Distribution coverage: Retail pharmacy and PBM coverage determines speed of conversion.
• Formulary tiering: PBMs move generics to preferred tiers after launch to drive substitution.

---

What litigation, settlements, and injunction outcomes typically shape TROXYCA ER revenue?

Answer (featured snippet): Settlement agreements and injunction outcomes are the principal tools that convert litigation uncertainty into a calendar-driven revenue impact.

Where settlements land commercially

• Delayed launch date: A fixed generic entry date, often coupled with marketing carve-outs and label restrictions.
• Stipulated damages frameworks: In some cases, brand pays or generic pays, typically reflected in legal expense rather than operating margin.

Why outcomes matter

• Settlements can stabilize net revenue and reduce forecast variance.
• Injunctions can pause entry and allow the brand to defend rebates and formulary positioning.

---

How does TROXYCA ER manufacturing and supply chain affect availability and sales?

Answer (featured snippet): Availability affects revenue because ER opioids are sensitive to supply disruptions that trigger therapeutic substitution.

Supply constraints that matter

• Line capacity and batch release: ER products require consistent release characteristics, increasing the impact of manufacturing deviations.
• Quality events: FDA inspections, recalls, and remediation can force temporary shipping pauses.
• Co-packers: Packaging and dosage-form-specific components can constrain distribution during shortages.

---

Financial trajectory dashboard for TROXYCA ER: what to model and how

Because audited sales, unit share, and recent quarterly revenue are not provided in the prompt, only a structural modeling blueprint is possible:

Model variables tied to market dynamics

• Net sales by quarter: Track pre-generic stability, rebate step changes, and post-launch cliff.
• Prescription starts and total patients: Use claims data to map demand compression from formulary edits.
• Wholesale acquisition cost dispersion: Proxy price erosion around launch.
• Gross-to-net bridge: Rebate and charge impacts from payer contracting cycles.
• Inventory and channel fill: Explains revenue spikes/dips in launch-adjacent quarters.

Revenue path under common entry curves

• Pre-entry: Flat to modest decline from policy pressure and substitution.
• Launch quarter: Discrete drop driven by immediate conversion for covered patients.
• Post-launch: Continued decline as generic market share grows and PBMs tighten step edits.

---

Key Takeaways

• TROXYCA ER’s market performance is primarily governed by formulary access, payer opioid controls, and net pricing dynamics rather than therapy differentiation alone.
• The exclusivity and patent estate in the Orange Book is the gating item for generic launch timing, settlement leverage, and revenue predictability.
• Post-generic erosion typically produces a sharp net sales step-down, then a continued decline governed by strength coverage, PBM tiering, and rebate contraction.
• Opioid class enforcement and utilization management can suppress new starts and increase churn, shaping the “baseline” trajectory even before exclusivity expires.

---

FAQs

1. How do PBM step edits change TROXYCA ER patient starts and persistence?
2. What does a Paragraph IV filing do to TROXYCA ER’s generic launch timeline?
3. Which factors determine how fast generic tapentadol ER products capture share after first launch?
4. How should investors model gross-to-net changes for TROXYCA ER during formulary re-contracting?
5. What manufacturing events for ER opioids most often cause short-term revenue drops through supply constraints?

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. U.S. FDA. Guidance documents on ANDA submission and therapeutic equivalence (bioequivalence).